Search This Blog

Thursday, August 2, 2018

Regeneron Pharma (REGN) PT Raised to $440 at Oppenheimer on Q2 Report


‘Eylea Static Decreasing, 2H18 Product Launches’. Oppenheimer raised its price target on Regeneron Pharma (NASDAQ: REGN) to $440.00 (from $410.00).
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)